The Philippines is the third-largest pharmaceutical market in ASEAN after Thailand and Indonesia. In 2019, total generic drug sales were PHP82.3 billion accounting for 63% of prescription sales and estimated to reach PHP110 Billion by 2024. The highest cost of medicines in the Philippines among ASEAN countries driving the purchase of more generic medicines than […]

Read More →

The US Food and Drug Administration (FDA) in 2019, has approved an increasing number of orphan drugs and biologics, as well as drugs targeted at specific cancers. The Center for Drug Evaluation and Research (CDER) has reported that this value was more than twice compared to the past eight years. Worldwide orphan drug sales are […]

Read More →